Moderna reports surprise profit, sets out road map for RSV vaccine, ET HealthWorld
London: Moderna on Thursday reported a surprise fourth-quarter profit, helped by cost cutting and deferred payments, and set out a commercial roadmap for its vaccines in Europe and experimental respiratory syncytial virus (RSV) shot. Shares jumped 8 per cent to $94.65 in early trading, still well off the record high of $497.49 hit during the…